![]() | ![]() |
Formats:
|
||||||||||||||||||||
Department of Chemistry, Oregon State University, 153 Gilbert Hall, Corvallis OR 97331, USA E-mail: rich.carter/at/oregonstate.edu The publisher's final edited version of this article is available free at Chem Commun (Camb). See other articles in PMC that cite the published article.Abstract The efficient syntheses of the ABCD ring system of the originally proposed structure of azaspiracid-1 and the ABCDE ring system of the revised structure of azaspiracid-1 containing the correct stereochemistry at C6, C10, C13, C14, C16, C17, C19, C21, C22, C24 and C25 have been achieved. Azaspiracid-1 (1) was discovered in 1995 when several individuals became ill after consuming mussels harvested from Killary Harbor in Ireland.1 Yasumoto and co-workers soon concluded a new toxin, azaspiracid-1 (1), was the cause of the outbreak in Ireland (Fig. 1
One particularly challenging portion of the azaspiracid architecture is the C10, C13 transoidal bisspiroketal moiety. This transoidal stereochemistry in 1 is proposed to exist with the C13 furan oxygen in an equatorial or “non-anomeric” orientation (Fig. 2
Recently, Nicolaou and co-workers revealed, in a series of impressive publications,9 that azaspiracid-1 was actually mis-assigned. They initially proposed an alternate structure 6 involving the relocation of the C8,9 alkene to the C7,8 position and the enantiomer of C28–C47 FGHI ring system (FGHI-ent).9a,b Nicolaou and co-workers asserted that movement of the alkene to the C7,8 position might address their observation of two inseparable compounds (presumably due to the bisspiroketal) versus the one isomer observed by Yasumoto. While the data put forth by Nicolaou to justify his proposed structure 6 was clearly enticing, we were troubled by the complications created by the relocation of the C8,9 olefin.2 It was not apparent to us what stereochemical difference would be relayed to the bisspiroketal by movement of the C8,9 alkene. It was our belief that the major error(s) in structural assignment of azaspiracid lay in the CD ring system. We were intrigued by the possibility that the actual structure of azaspiracid might instead possess the epimeric C14 stereocenter (e.g. compound 8). This modification would potentially allow the C13 spiroketal to return to its preferred anomeric conformation (Fig. 2
Synthesis of the keto phosphonate 11 began from the commercially available Masamune auxiliary (Scheme 2
The synthesis of the northern portion of azaspiracid commenced with previously reported ketone 157e (Scheme 3
Synthesis of the required aldehyde began with the readily available Evans alkylated product 24 (Scheme 4
Our standard Julia coupling approach7c,f with the previously prepared sulfone 277a followed by TPAP oxidation gave the keto sulfone 28 (Scheme 5
With the synthesis of the lactone 30 complete, conversion to the ABCDE ring system was undertaken (Scheme 6
Comparison of the NMR spectra of synthetic 33 and 34 and azaspiracid-1 in identical solvents (CD3OD + 0.5% CD3CO2D) revealed some intriguing results. Large sections of the synthetic materials 33 and 34 were in good agreement with published data for azaspiracid-1.2 Major points of divergence proved to be the H8,9 alkene position and H6 (1H NMR: 33 H6 = 4.36, 34 H6 = 4.35, azaspiracid-1 H6 = 4.81; 33 H8 = 5.94, 34 H8 = 5.95, azaspiracid-1 H8 = 5.76). Given the results presented, we concluded that the relocation of the alkene to the C7,8 position (e.g. compound 7) was necessary for the actual structure of azaspiracid-1. Subsequent to this conclusion, Professor Nicolaou independently reported the confirmation of this assignment.9d In summary, efficient approaches to the originally proposed ABCD ring system (17 steps from oxazolidinone ent-23) and the revised ABCDE ring system (21 steps from oxazolidinone 23) of azaspiracid are presented. It is important to note that acid 34 contains the correct stereochemistry at C6, C10, C13, C14, C16, C17, C19, C21, C22, C24 and C25 necessary for the actual structure of azaspiracid-1 (7).9d Key transformations include the Wadsworth–Emmons coupling to form the C19,20 linkage and bisspiroketalization of the ketone 28 to provide a single transoidal bisspiroketal 29. Further progress toward the total synthesis of the actual structure of azaspiracid-1 (7) will be reported in due course. Financial support was provided by the National Institutes of Health (GM63723). We thank Professor Michael Doyle (University of Maryland) for his generous gift of the rhodium catalysts. The authors would also like to thank Professor Max Dienzer (OSU) and Dr. Jeff Morre′ (OSU) for mass spectral data, Roger Kohnert (OSU) for NMR assistance, Professor David A. Horne (OSU), Dr. Daniel P. Furkert (OSU) and Dr. Roger Hanselmann (Rib-X Pharmaceuticals) for their helpful discussions. Expt Section Click here to view.(809K, pdf) NMR Spectra Click here to view.(2.1M, pdf) Footnotes †Electronic Supplementary Information (ESI) available: Complete experimental procedures and 1H and 13C spectra are provided for all new compounds. See http://www.rsc.org/suppdata/cc/b4/b410092a/ ‡Dedicated to Professor Li-Xin Dai on the occasion of his 80th birthday. Notes and references 1. MacMahon T, Silke J. Harmful Algae News. 1996;14:2. 2. Satake M, Ofuji K, Naoki H, James KJ, Furey A, McMahon T, Silke J, Yasumoto T. J Am Chem Soc. 1998;120:9967–68. 3. Furey A, Moroney C, Magdalena AB, Fidalgo Saez MJ, Lehane M, James KJ. Environ Sci Technol. 2003;37:3078–84. [PubMed] 4. James KJ, Furey A, Lehane M, Ramstad H, Aune T, Hovgaard P, Morris S, Higman W, Satake M, Yasumoto T. Toxicon. 2002;40:909–15. [PubMed] 5. James KJ, Moroney C, Roden C, Satake M, Yasumoto T, Lehane M, Furey A. Toxicon. 2003;41:145–51. [PubMed] 6. Ito E, Satake M, Ofuji K, Kurita N, McMahon T, James K, Yasumoto T. Toxicon. 2000;38:917–30. [PubMed] 7. (a) Carter RG, Weldon DJ. Org Lett. 2000;2:3913–16. [PubMed] (b) Carter RG, Weldon DJ, Bourland TC. 221st National ACS Meeting; San Diego, ORG-479. [PubMed] (c) Carter RG, Graves DE. Tetrahedron Lett. 2001;42:6035–39. [PubMed] (d) Carter RG, Bourland TC, Graves DE. Org Lett. 2002;4:2177–79. [PubMed] (e) Carter RG, Graves DE, Gronemeyer MA, Tschumper GS. Org Lett. 2002;4:2181–4. [PubMed] (f) Carter RG, Bourland TC, Zhou X-T, Gronemeyer MA. Tetrahedron. 2003;59:8963–74. [PubMed] 8. (a) Dounay AB, Forsyth CJ. Org Lett. 2001;3:975–78. [PubMed] (b) Aiguade J, Hao J, Forsyth CJ. Org Lett. 2001;3:979–82. [PubMed] (c) Aiguade J, Hao J, Forsyth CJ. Tetrahedron Lett. 2001;42:817–20. [PubMed] (d) Hao J, Aiguade J, Forsyth CJ. Tetrahedron Lett. 2001;42:821–24. [PubMed] (e) Nicolaou KC, Pihko PM, Diedrichs N, Zou N, Bernal F. Angew Chem Int Ed. 2001;40:1262–65. [PubMed] (f) Buszek KR. 221st National ACS Meeting; San Diego, ORGN-570. [PubMed] (g) Forsyth CJ, Hao J, Aiguade J. Angew Chem Int Ed. 2001;40:3663–67. [PubMed] (h) Nicolaou KC, Qian W, Bernal F, Uesaka N, Pihko PM, Hinrichs J. Angew Chem Int Ed. 2001;40:4068–71. [PubMed] (i) Sasaki M, Iwamuro Y, Nemoto J, Oikawa M. Tetrahedron Lett. 2003;44:6199–201. [PubMed] (j) Buszek KR, Gibson TS, Reinhardt BC, Sunde JR. 226th ACS National Meeting; New York, ORGN-179. [PubMed] (k) Ishikawa Y, Nishiyama S. Tetrahedron Lett. 2004;45:351–54. [PubMed] (l) Ishikawa Y, Nishiyama S. Heterocycles. 2004;63:539–65. [PubMed] (m) Ishikawa Y, Nishiyama S. Heterocycles. 2004;63:885–93. [PubMed] 9. (a) Nicolaou KC, Li Y, Uesaka N, Koftis TV, Vyskocil S, Ling T, Govindasamy M, Qian W, Bernal F, Chen DY-K. Angew Chem Int Ed. 2003;42:3643–48. (b) Nicolaou KC, Chen DY-K, Li Y, Qian W, Ling T, Vyskocil S, Koftis TV, Govindasamy M, Uesaka N. Angew Chem Int Ed. 2003;42:3649–53. (c) Nicolaou KC, Vyskocil S, Koftis TV, Yamada YMA, Ling T, Chen DY-K, Tang W, Petrovic G, Frederick MO, Satake YM. Angew Chem Int Ed. 2004;43:4312–4318. (d) Nicolaou KC, Koftis TV, Vyskocil S, Petrovic G, Ling T, Yamada YMA, Tang W, Frederick MO. Angew Chem Int Ed. 2004;43:4318–4324. 10. Abiko A, Liu J-F, Masamune S. J Am Chem Soc. 1997;119:2586–87. 11. Inoue T, Liu J-F, Buskke DC, Abiko A. J Org Chem. 2002;67:5250–56. [PubMed] 12. Myers AG, McKinstry L. J Org Chem. 1996;61:2428–40. 13. Dounay and Forsyth have reported isolation of an additional bisspiroketal product from selected conditions. Their compound was assigned to be the C14-epi product bearing a cisoidal bisspiroketal. See ref. 8a and A. B. Dounay, Ph.D. 2001, University of Minnesota, pp. 160–166. 14. Freeman PK, Hutchinson LL. J Org Chem. 1980;45:1924–30. 15. Doyle MP, Catino AJ. Tetrahedron: Asymm. 2003;14:925–28. 16. Wee AGH. J Org Chem. 2001;66:8513–17. [PubMed] 17. Doyle MP, Zhou Q-L, Raab CE, Roos GHP, Simonsen SH, Lynch V. Inorg Chem. 1996;35:6064–73. 18. Kolb HC, VanNieuwenhze MS, Sharpless KB. Chem Rev. 1994;94:2483–547. 19. See ESI for full account of Mosher model. I. Ohtani T, Kusumi Y, Kashman Kakisawa H J Am Chem Soc. 1991;113:4092–96. 20. Boger DL, Ichikawa S, Zhong W. J Am Chem Soc. 2001;123:4161–67. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Environ Sci Technol. 2003 Jul 15; 37(14):3078-84.
[Environ Sci Technol. 2003]Toxicon. 2002 Jul; 40(7):909-15.
[Toxicon. 2002]Toxicon. 2003 Feb; 41(2):145-51.
[Toxicon. 2003]Toxicon. 2000 Jul; 38(7):917-30.
[Toxicon. 2000]Org Lett. 2000 Nov 30; 2(24):3913-6.
[Org Lett. 2000]Org Lett. 2000 Nov 30; 2(24):3913-6.
[Org Lett. 2000]Org Lett. 2001 Apr 5; 3(7):975-8.
[Org Lett. 2001]J Org Chem. 2002 Jul 26; 67(15):5250-6.
[J Org Chem. 2002]Org Lett. 2000 Nov 30; 2(24):3913-6.
[Org Lett. 2000]J Org Chem. 2001 Dec 14; 66(25):8513-7.
[J Org Chem. 2001]Org Lett. 2000 Nov 30; 2(24):3913-6.
[Org Lett. 2000]Org Lett. 2000 Nov 30; 2(24):3913-6.
[Org Lett. 2000]J Am Chem Soc. 2001 May 9; 123(18):4161-7.
[J Am Chem Soc. 2001]